M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia
TL;DR: To assess long‐term treatment patterns and outcomes in patients with persistent or chronic immuneThrombocytopenia (ITP), also considering the impact of the treatment with thrombopoietin receptor agonists (TPO‐RAs) prior to splenectomy.
Journal ArticleDOI
Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
Roberto Mina,Alessandra Larocca,Massimo Offidani,Sara Bringhen,Tommaso Caravita,Valeria Magarotto,Lucia Pantani,Francesco Di Raimondo,Alberto Bosi,Iolanda Vincelli,Paola Tacchetti,Gianluca Gaidano,Sonia Grandi,Caterina Musolino,Chiara Cerrato,Ludek Pour,Monica Astolfi,Giuseppe Rossi,Fausto Rossini,Maria Teresa Petrucci,Roberto Ria,Annalisa Pezzi,Roman Hájek,Michele Cavo,Andrew Spencer,Mario Boccadoro,Antonio Palumbo +26 more
TL;DR: The impact of CR on overall-survival (OS) and progression-free survival (PFS) and its relationship with age (young vs elderly patients) and type of treatment (ASCT vs conventional chemotherapy [CC]) is evaluated.
Thromboprophylaxis for Newly Diagnosed Multiplemyeloma Patients Treated With Lenalidomide-Basedregimens: A Randomized Phase Iii Study of Aspirinvs Enoxaparin
Alessandra Larocca,Federica Cavallo,Andrea Evangelista,F. Di Raimondo,Lucio Catalano,Monica Galli,Clotilde Cangialosi,Giulia Benevolo,D. Rossi,Tommasina Guglielmelli,Luciano Masini,Francesca Rossi,Roberto Ria,Nicola Cascavilla,Norbert Pescosta,Anna Baraldi,Magda Marcatti,T. Caravita di Toritto,Arnon Nagler,Mario Boccadoro,Antonio Palumbo +20 more
Covid-19 and myeloma
TL;DR: It is agreed that MM pts should ideally be vaccinated before onset of active disease and/or during periods of well controlled disease, and a third dose should be administered after an interval of approximately 6 months, and early data in immunocompromised pts show a vaccination response in several previously poorly responding pts after a forth dose.
Journal ArticleDOI
Bortezomib and Plasma Cell Leukemia.
Pellegrino Musto,Marialucia Barone,Roberto Guariglia,Giuseppe Pietrantuono,Fausto Rossini,Tommasina Guglielmelli,Vincenzo Pitini,Felicetto Ferrara,Monica Galli,Antonietta Falcone,Samantha Pozzi,Fiorella D'Auria,Stefano Sacchi,Mario Boccadoro,Antonio Palumbo +14 more
TL;DR: Bortezomib (Velcade) is currently approved in USA and EU for the treatment of resistant/relapsed multiple mieloma (MM) as discussed by the authors, but there are very few data about the efficacy of this drug in plasma cell leukemia (PCL), a MM variant usually characterized by very poor prognosis.